CLINICAL INVESTIGATION : Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity

• 資料種別: 記事
• タイトル: CLINICAL INVESTIGATION : Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity
• 著者・編者: Ryusaburo Mori; Mitsuko Yuzawa; Eriko Akaza 他
• 著者標目: Ryusaburo Mori; Mitsuko Yuzawa; Eriko Akaza
• タイトル（掲載誌）: Japanese journal of ophthalmology : the official international journal of the Japanese Ophthalmological Society / Japanese Ophthalmological Society
• 巻号年月日等（掲載誌）: 57(4):2013.7・8
• 掲載巻: 57
• 掲載号: 4
• 掲載ページ: 365-371
• 掲載年月日（W3CDTF）: 2013
• ISSN（掲載誌）: 0021-5155
• 出版事項（掲載誌）: [Tokyo] : [Springer Japan]
• 出版地（国名コード）: JP
• 本文の言語コード: eng
• 件名標目: Polypoidal choroidal vasculopathy; Ranibizumab; Visual outcome
• NDLC: ZS42
• 対象利用者: 一般
• 所蔵機関: 国立国会図書館
• 請求記号: Z53-D450
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館雑誌記事索引; https://ndlsearch.ndl.go.jp
• 書誌ID（NDLBibID）: 024692012; http://id.ndl.go.jp/bib/024692012
• 整理区分コード: 632

• 要約等: To evaluate the efficacy of intravitreal ranibizumab (IVR) for subfoveal polypoidal choroidal vasculopathy (PCV) in eyes with a best corrected visual acuity (BCVA) of 0.6 (logMAR 0.22) or better.Fifty eyes with BCVA between 0.6 (logMAR 0.22) and 1.0 (logMAR 0) and subfoveal PCV were treated with IVR for 3 consecutive months. Additional IVR was given at subsequent monthly visits, if needed, up to 11 months after the initial injection. The patients were followed-up prospectively for 12 months, and changes in mean BCVA, central retinal thickness (CRT), serous retinal detachment (SRD), hemorrhage, and number of polypoidal lesions were evaluated.Mean BCVA improved significantly at the 3-, 6-, 9-, and 12-month follow-up visits and CRT decreased significantly at 1, 2, 3, 6, 9, and 12 months after the initial treatment as compared with the baseline. SRD was observed in 10 and 21 eyes at 3 and 12 months. Hemorrhage was observed in 6 eyes at 3 months and 3 eyes at 12 months. All polypoidal lesions had completely regressed in 19 % and the size of network vessels was either unchanged or enlarged in 98 % of the eyes at 12 months.Based on the maintenance of vision improvement for at least 12 months, IVR for PCV proved useful for eyes with BCVAs of 0.6 (logMAR 0.22) to 1.0 (logMAR 0), despite a low regression rate of polypoidal lesions and minimal network size reduction.
• DOI: 10.1007/s10384-013-0245-9; https://doi.org/10.1007/s10384-013-0245-9
• 関連情報（URI）: http://id.ndl.go.jp/bib/024692012; https://ndlsearch.ndl.go.jp/books/R000000004-I024692012; http://link.springer.com/content/pdf/10.1007/s10384-013-0245-9.pdf; http://link.springer.com/article/10.1007/s10384-013-0245-9/fulltext.html; http://link.springer.com/content/pdf/10.1007/s10384-013-0245-9; https://search.jamas.or.jp/link/ui/2014247141
• 参照: One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1360002216104257664; Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps; https://cir.nii.ac.jp/crid/1360004231949705216; INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY; https://cir.nii.ac.jp/crid/1360283692733202816; Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study; https://cir.nii.ac.jp/crid/1360285711022549760; Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity; https://cir.nii.ac.jp/crid/1360285711379274496; Three‐year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy; https://cir.nii.ac.jp/crid/1360567185427867520; 加齢黄斑変性の抗VEGF 療法; https://cir.nii.ac.jp/crid/1390001206432378240; CLINICAL INVESTIGATION : Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy; https://cir.nii.ac.jp/crid/1522543655342679680
• 参照: Clinical investigation: Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab; https://cir.nii.ac.jp/crid/1050282677154823424; Short-Term Anatomic Effect of Ranibizumab for Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1360011143899273472; Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy; https://cir.nii.ac.jp/crid/1360292619638280064; Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results; https://cir.nii.ac.jp/crid/1360292620474470272; Polypoidal choroidal vasculopathy: natural history; https://cir.nii.ac.jp/crid/1360574094799652608; Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy; https://cir.nii.ac.jp/crid/1360574094871383424; Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin; https://cir.nii.ac.jp/crid/1360574095518122752; Ranibizumab for Neovascular Age-Related Macular Degeneration; https://cir.nii.ac.jp/crid/1360574096152025088; Two-Year Results of Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1360584342603159680; Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy; https://cir.nii.ac.jp/crid/1361137043570317056; Long-Term Results of Photodynamic Therapy of Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1361137044405562496; Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials; https://cir.nii.ac.jp/crid/1361137045140389760; INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH GOOD BASELINE VISUAL ACUITY; https://cir.nii.ac.jp/crid/1361137045378385408; One-Year Results of Three Monthly Ranibizumab Injections and As-Needed Reinjections for Polypoidal Choroidal Vasculopathy in Japanese Patients; https://cir.nii.ac.jp/crid/1361418519421708160; The Therapeutic Effects of Intravitreal Bevacizumab in a Patient with Recalcitrant Idiopathic Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1361699996170450560; Role of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1361981468421735552; One-Year Outcomes of Photodynamic Therapy in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese Patients; https://cir.nii.ac.jp/crid/1361981471256559616; Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1362262944310355968; IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV); https://cir.nii.ac.jp/crid/1362262945752304000; Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration; https://cir.nii.ac.jp/crid/1362544418908483968; Photodynamic Therapy with Verteporfin in the Treatment of Exudative Idiopathic Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1362544420182443776; TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY WITH PHOTODYNAMIC THERAPY; https://cir.nii.ac.jp/crid/1362544421317077632; Photodynamic Therapy with Verteporfin for Polypoidal Choroidal Vasculopathy of the Macula; https://cir.nii.ac.jp/crid/1362825894746879744; EVEREST STUDY; https://cir.nii.ac.jp/crid/1362825895027006464; Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation; https://cir.nii.ac.jp/crid/1363107370661078528; Clinicopathologic Findings in Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1363951793535998080; Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin; https://cir.nii.ac.jp/crid/1363951795230488832; Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy; https://cir.nii.ac.jp/crid/1364233269825610624; Clinical investigations: Role of photodynamic therapy in polypoidal choroidal vasculopathy; https://cir.nii.ac.jp/crid/1521699230361010688; Clinical investigation: Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy; https://cir.nii.ac.jp/crid/1521980705254530816
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp; Crossref; https://www.crossref.org; CiNii Articles
• 書誌ID（NDLBibID）: 024692012; http://id.ndl.go.jp/bib/024692012
• NII論文ID: 10031189425